Breast cancer - bevacizumab (in combination with a taxane): evaluation report
Breast cancer - bevacizumab (in combination with a taxane): pre-meeting briefing
Breast cancer - bevacizumab (in combination with a taxane): evidence review group report
Breast cancer - bevacizumab (in combination with a taxane): evidence review group report - factual accuracy check
Breast cancer - bevacizumab (in combination with a taxane): non-manufacturer submissions
Breast cancer - bevacizumab (in combination with a taxane): manufacturer submissions
Breast cancer - bevacizumab (in combination with a taxane): expert written personal statements
This page was last updated: 19 February 2011
